Skip to content
drillr.ai

ANVS

Annovis Bio, Inc.

NYSE · USHealthcareBiotechnology
$1.69-2.87%

Price as of Jul 20, 2026

ANVS news

Annovis Bio, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

    MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of 7,895,000 shares of its common stock and accompanying warrants to purchase up to 7,105,500 shares of common stock. The combined

    Globe Newswire ·

  2. Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

    MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) accompanying warrants to purchase shares of common stock. Th

    Globe Newswire ·

  3. Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

    * Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026 * PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026 * New Drug Application (NDA) for buntanetap as a symptomatic treatment for AD is expected in early 2027 and as a potential disease-modifying treatment in early 2028 MALVERN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage bio

    Globe Newswire ·

  4. Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

    MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten offering of 5,263,156 shares of its common stock, together with accompanying warrants to purchase up to 5,263,156 shares of common stock. The com

    Globe Newswire ·

  5. The Credibility Filter Wall Street Uses to Sort Biotech Winners

    VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid or late stage clinical data([1]). That is not a coincidence. The IQVIA Institute's latest annual report found that biopharma dealmaking is now clustering around high value science and companies with credentialed pipelines([2]). It’s becoming apparent that smart money is no longer ch

    Globe Newswire ·

  6. Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

    MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the issuance of U.S. Patent No. 12,582,632 B2, covering prevention and treatment of neurological injuries arising from brain infections through the administration of buntanetap

    Globe Newswire ·

  7. Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

    MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced business updates and reported financial results for the fiscal year 2025. In 2025, Annovis achieved a significant milestone in its clinical development program with the initiat

    Globe Newswire ·